Cancer Therapy

Independent laboratory and Merck & Co., Inc., sign oncology research partnership

Published in Cancer Weekly, August 31st, 2004

Pierre Fabre Medicament has signed a collaborative research, development and license agreement with Merck & Co., Inc., for F50035, Pierre Fabre Medicament's recombinant humanized antibody targeted against the insulin-like growth factor (IGF-1) receptor. F50035 is currently in preclinical development for the treatment of cancer.

Under the terms of the agreement, both partners will participate in a 3-year, renewable research program aimed at completing characterization of the antitumor activity of F50035 and identifying back-up antibodies.

Merck will be responsible for development and manufacturing of F50035. Merck is receiving worldwide marketing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-08-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry